London, Canada, April 15th, 2024— Pulse Infoframe, is delighted to announce the establishment of its Scientific Advisory Board (SAB). This distinguished board will further bolster and refine Pulse Infoframe’s clinical and scientific direction, particularly emphasizing the pivotal role of real-world data (RWD) in the development of novel therapies.
Comprised of esteemed thought leaders with extensive backgrounds in life sciences, drug development and policy the SAB will provide invaluable insights guiding the advancement of Pulse Infoframe’s innovative technology, services, and advanced analytics roadmap. Dr. Femida Gwadry-Sridhar, CEO and founder of Pulse Infoframe, affirms, “The SAB will be instrumental in driving evidence-based insights derived from real-world data to accelerate the drug process, benefiting the rare disease and cancer communities we serve.”
The Scientific Advisory Board consists of five distinguished members:
- Gerry Cox, a renowned clinical geneticist at Boston Children’s Hospital and founder of Gerald
- Cox Rare Care Consulting, LLC. Cox served as the Vice President of Clinical Development for Rare Diseases at Genzyme (now Sanofi), overseeing the clinical development of enzyme replacement and substrate reduction therapies for lysosomal storage disorders. He also held the position of Chief Medical Officer at Editas Medicine.
- Ruben Giorgino, founder and managing director of Triallism GmbH, with over three decades of clinical research experience, including extensive tenure in the development pharmaceutical industry. Dr. Giorgino has held roles at Azafaros B.V., Helsinn Group and Actelion.
- Ali Hairi, VP of Clinical Development and Medical Affairs at LG Chem Life Sciences & Chief Medical Officer at Eloxx Pharmaceuticals. Dr Hariri has also served as the Global Project Head for Sanofi and spent time in clinical development at Takeda and Ionis while being a practicing nephrologist.
- Michael B. Nichol, PhD, Professor Emeritus of Public Policy at the University of Southern California, renowned for his consultancy work with prominent organizations such as Amgen, Glaxo SmithKline, Pfizer, and Novartis. Nichol’s has published extensively on topics such as cost-effectiveness of pharmaceutical interventions, health care cost and resource utilization, medication and therapeutic persistency, and health utility measurement.
- Sheela Upadhyaya, a distinguished life sciences consultant specializing in rare diseases, notable for her leadership in critical initiatives for NHS England, led the UK National Institute for Health and Care Excellence (NICE) Highly Specialized Technology program which evaluates medicines and technologies for rare and ultra-rare conditions. She brings over 25 years of experience working in healthcare research, infrastructure, and market access strategy.
Together, the Scientific Advisory board will further support the technological and scientific rigor of Pulse’s leading research approach.
Drawing on their collective expertise, the SAB will assist in making informed decisions related to research priorities, methodologies, and resource allocation, ultimately optimizing the impact and success of Pulse Infoframe’s initiatives. As Pulse Infoframe further extends its registries globally, the SABs insights will further support the development of Patient Reported Outcome Measures that are of high scientific rigor and lend themselves well to localization efforts, as well as extending the network of leading researchers and PIs globally.
“I’m excited to join the Pulse Infoframe Scientific Advisory Board and work with my esteemed colleagues to advance the understanding and management of a platform approach to collecting real world data. Together, we will work to revolutionize a new approach led by Pulse to generate data, harness the power of collective knowledge and drive meaningful change.” – Dr. Gerry Cox
For more information about Pulse Infoframe, visit www.PulseInfoframe.com.
-30-
Pulse Infoframe is a pioneer and leading provider in the life science industry with a real-world evidence (“RWE”) generation platform enabling acceleration of scientific research and the development of new therapeutic products. Pulse’s enterprise-grade platform adaptive technology is trusted by a global, ‘blue-chip’ customer base of top pharma companies, patient advocacy groups and academic medical centers. Learn more at www.pulseinfoframe.com.
